Objectives: The aim of this study was to establish whether there was a relationship between the number of antibacterial agents used and total antibiotic use in European hospitals.
Introduction
Recently, Monnet et al. 1 and Marra et al. 2 independently reported on a relationship between antibiotic consumption and drug availability in the context of the outpatient setting. Monnet et al. 1 found that community consumption of antibacterials in European countries was related to the number of trade names for oral antibacterial agents registered in these countries. Marra et al. 2 looked at trends in antibiotic consumption associated with the listing of new agents on the drug formulary in British Columbia, Canada, over a 5 year period. They found that listing of a new antibiotic on the formulary was followed by a temporary increase in use of the agent.
The Antibiotic Resistance, Prevention And Control (ARPAC) study collected data on antibiotic use in European hospitals in 2001. The aim of the present investigation was to establish whether there was any relationship between the numbers of different antibiotics used in ARPAC participating hospitals and total, quantitative antibiotic use in these hospitals.
Materials and methods
This was an observational, cross-sectional study whereby hospital antibiotic use data for 2001 were collected as part of a Concerted Action project (ARPAC) funded by the European Commission (project number QLK2- CT-2001-00915 The numbers of different antibiotics used per hospital were calculated at the fifth of five levels for the ATC J01 class and were differentiated by route of administration (http://www.whocc.no/ atcddd/indexdatabase). Drugs are divided into 14 main groups (first level), with 1 pharmacological/therapeutic subgroup (second level). The third and fourth levels are chemical/pharmacological/therapeutic subgroups and the fifth level is the chemical substance.
Statistical analysis
Data were entered into a Microsoft Access database and analysis was conducted using SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA). The Kruskal-Wallis test was used to compare variables across geographical regions. Spearman rank correlations were computed to investigate the relationship between total antibiotic use and number of different agents used.
Results
The median number of different antibacterial agents used per hospital was 46 [interquartile range (IQR) = 39-55, min = 16, max = 82] and varied significantly by geographical region (Figure 1 ) (Kruskal-Wallis test, P = 0.001).
The most frequently used antibiotic in each hospital accounted for a median of 16.5% (IQR = 12.8-24.2, min = 7.2, max = 60.9) of total use, whereas the 5 most frequently used antibiotics accounted for 53.3% (IQR = 44.8-57.5, min = 32.3, max = 84.1) and the 10 most frequently used antibiotics for 73.7% (IQR = 64.8-79.0, min = 53.0, max = 98.5) of total use. Overall, the most frequently used antibiotic was the oral formulation of the combination amoxicillin/clavulanic acid, followed by the parenteral formulation of this combination, followed by oral ciprofloxacin, parenteral cefuroxime and oral amoxicillin. We found a statistically significant relationship between the number of different antibacterial agents used in each hospital and total use of these drugs (Spearman's rank, r = 0.40, P < 0.01) (Figure 2 ). When correlations were investigated in each of the five geographical regions, however, significant correlations were found only in Western and Southern Europe ( Table 2) .
Discussion
To our knowledge, this is the first Europe-wide survey of hospital-level antibiotic use, although the European Surveillance of Antibiotic Consumption (ESAC) project has collated aggregate hospital data for individual countries. 4 Comparison with data from ESAC is however not possible as ESAC has used a non-standard unit of measuring antibiotic use (DDDs/1000 inhabitants/day), whereas the current study used the WHO recommended unit (DDD/100 occupied bed-days), which is well standardized and considered to be optimum when investigating antibiotic resistance selection pressure. 
Denmark (n = 6) Austria (n = 6) Bulgaria (n = 6) Albania (n = 0) Greece (n = 7) Finland (n = 0) Belgium (n = 20) Czech Republic (n = 3) Bosnia (n = 0) Israel (n = 2) Netherlands (n = 5) France (4) Estonia (n = 2) Croatia (n = 5) Italy (n = 6) Norway (n = 4) Germany (10) Hungary (n = 3) Macedonia (n = 0) Malta (n = 1) Sweden (n = 4) Luxembourg (n = 0) Latvia (n = 1) Yugoslavia (n = 3) Portugal (n = 1) Switzerland (n = 3) Lithuania (n = 3) Spain (n = 4) UK (9) Poland (n = 6) Turkey (n = 6) Romania (n = 1) Russia (n = 1) Slovakia (n = 3) Slovenia (n = 4)
The ARPAC project collated and analysed several different datasets including antibiotic resistance prevalence for a range of organisms, antibiotic susceptibility testing methods used, typing methods used, antibiotic policies and practices as well as infection control policies and practices. The lowest response amongst participating hospitals was to the request for antibiotic use data. Many of the hospitals had never collated their antibiotic use data before and this proved prohibitively problematic for some.
Despite this, numbers of hospitals that provided antibiotic use data were greater than those that have taken part in similar studies in the USA. [5] [6] [7] Thus, the strengths of this pan-European study do include the large sample of recruited hospitals as well as rigorous, piloted data collection methods and high quality data obtained from participating hospitals. We acknowledge that hospitals were self-selecting, increasing the risk of response bias, and coverage was sparse in some countries. Country-level hospital data were obtained from EUROSTAT 8 and crude estimated coverage of European acute care beds was estimated to be 10% or less per country. This however is likely to be an underestimate as the EUROSTAT denominator value often included psychiatric, long-stay and community beds. Despite this disappointing coverage, other datasets, including the antibiotic resistance prevalence data gathered, were comparable with other European Commission surveillance projects. 9 In the context of well-publicized antibiotic resistance problems as well as relationships between antibiotic use and resistance, the results of the present study are not surprising, showing Southern Europe to have the highest levels of total antibiotic use. Similar findings have also been described for antibiotic use in primary care. 10 The relative closeness of the median total antibiotic use in Western and Northern Europe in the current study is, perhaps, more surprising although the West exhibited a much wider range than the North. The fact that Central and Eastern Europe had the lowest antibiotic use might have been anticipated due to their less developed economies and previously centralized healthcare systems.
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It is probably fair to assume that virtually every agent listed on a hospital formulary is used to a greater or lesser extent in any year. As the data supplied by the ARPAC participating hospitals listed consumption for 2001, down to the last tablet, capsule or 13 Further analyses are needed to study the influence of different patterns of antibiotic use on resistance in ARPAC hospitals.
The findings of this hospital-based study were very similar to the community-based findings of Monnet et al. 1 Across all participating hospitals, there was a significant relationship between the number of different antibiotics used in 2001 and total use of antibiotics, although this association only explained 16% of the variation in total use. When correlations were also explored on a regional basis, they were only significant in Western and Southern Europe, where 32% and 45% of the variation in total use, respectively, could be explained by the number of different antibiotics available. Notably, these two regions had the highest antibiotic use. It should be noted however that numbers in South-Eastern Europe were too small to explore correlations with any confidence, with only eight contributing hospitals.
In summary, total antibiotic use in European hospitals is highly variable, as is the number of different antibacterial agents used. In general, we found a significant relationship between the number of antibiotics used and the total use of these drugs and this was most robust in Western and Southern Europe. One way of controlling antibiotic use may be to narrow the choice of available agents, while maintaining heterogeneity of the different antibiotics used to reduce resistant selection pressures. Rigorous intervention studies with assessment of patient outcome are required however, before antibiotic restriction could be widely implemented.
